Castle Biosciences, Inc. (NASDAQ: CSTL) is a Healthcare company (Medical - Diagnostics & Research) with a market capitalization of $1.0B. The Maz Rating grades it against the other companies in its sector.
Castle Biosciences, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $32.98, Castle Biosciences, Inc. trades at 2.7x sales and 2.1x book value. Over the last twelve months it generated about $376M of revenue and a net loss of $24M. It runs a gross margin of 77.1%, an operating margin of -7.4% and a net margin of -6.1%. It shows return on equity of -4.9%, return on invested capital of -5.4% and a free cash flow yield of 0.4%. On the balance sheet: a debt-to-equity ratio of 0.08 and a current ratio of 5.28. Over the past 52 weeks the share price ranged from $17.72 to $44.28, with a beta of 0.95.
Castle Biosciences, Inc. does not currently pay a dividend.
11 Wall Street analyst ratings cover the stock: 11 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.